Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07664631

Effects of Stimulant Medications in PTSD

Conditions: Adderall, PTSD, Post Traumatic Stress Disorder

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 40
Sponsor: University of Chicago

Location: University of Chicago Chicago Illinois

Summary

While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.

Eligibility Criteria

Inclusion Criteria: * Age 18 - 65 years old * BMI 19-30 kg/m2 * English fluency Exclusion Criteria: * Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder * Individuals with current acute or high risk of suicide or suicide attempt in past 6 months * Individuals with current psychotic or bipolar disorder * Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder * Individuals with chronic (non-PRN) treatment with antipsychotic drug (except PRN quetiapine 25mg PO qHS) or D2 antagonist * Individuals with medications with significant PD or PK interactions * Individuals with current treatment with a stimulant medication * Individuals with court or legally mandated treatment * Individuals with unstable or untreated medical disorder that would increase the risk of serious side effects of study drug (unstable hypertension, tachycardia, cardiac arrhythmia, recent MI or stroke, clinically significant neuropsychiatric or neurological disorder) * Members of a vulnerable population * High blood pressure (\>140/90) * Women who are pregnant, breastfeeding, or planning to become pregnant

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07664631). StuddyBuddy aggregates publicly available trial information.